

Variopeptyl® 0.1 mg

Triptorelin Acetate 0.1 mg



Variopeptyl® 0.1 mg contains triptorelin, a GnRH agonist which is used for hormonal therapy. It is indicated for the down-regulation of the pituitary before and during controlled ovarian hyper stimulation in assisted reproduction techniques.

Variopeptyl® 0.1 mg comes in convenient, patient-friendly pre-filled syringes reducing the risk of infection or patient dosing errors sometimes associated with multi-dose vials and syringes.

Variopeptyl® 0.1 mg is used to prevent premature ovulation by down-regulating the female hormone LH (Luteinizing Hormone). Premature ovulation occurs when levels of the female hormone LH are elevated, which can reduce the chances of getting pregnant.



Swiss Made API
Prefilled Safe & effective

No 5, Laleh St, Sattari Highway, Tehran-IRAN | Postal Code: 1473896381
T: +98 21 444 83 009 | F: +98 21 444 82 758 | For patient support program please call +98 920 947 6440
www.varianpharmed.com

Variopeptyl® 0.1 mg

Triptorelin Acetate 0.1 mg

Variopeptyl® 0.1 mg is a safe and effective choice in the GnRH long protocol which is offering your patients better results in controlled ovulation stimulation with lower risks compared to the GnRH antagonist protocol which has been proven to result in lower follicular production and a higher risk of major and minor congenital malformations.

Variopeptyl® 0.1 mg is a solution for injection, containing 0.1mg/1ml of triptorelin acetate in a prefilled syringe. It is used in different IVF protocols

Variopeptyl® 0.1 mg is indicated for Down regulation and prevention of premature luteinizing hormone (LH) surge in women undergoing controlled ovarian hyper stimulation for assisted reproductive technology (ART).

Variopeptyl 0.1 mg could make a real difference to your patients' wellbeing:

- ▶ Preventing LH surges using Variopeptyl 0.1 mg improves oocyte yield with more embryos, allowing better selection and, therefore, leading to an increase in pregnancy rates
- ▶ Increases the efficacy of IVF treatment
- ▶ Reduces cancellations of IVF protocol
- ▶ Reduced incidences of Ovarian Hyper-Stimulation Syndrome (OHSS)
- ▶ Improved response to gonadotropins
- ▶ Prevention of functional cysts and spontaneous pregnancy
- ▶ Prevention of LH surges




Overall, the GnRH agonist long protocol showed better overall clinical results in controlled ovarian stimulation, resulting in a greater number of mature follicles, with comparatively lower risks compared to the antagonist protocol.

A close assessment of cost benefit factors demonstrates that the GnRH agonist long protocol is a better option for IVF stimulation compared to the antagonist and minimal stimulation protocols.


the main goal of COH is to obtain a greater numbers of mature follicles by suppressing the premature LH surge. GnRH agonist long protocol achieves a higher number of mature follicles compared to the other protocols and undoubtedly offers advantages of higher number of oocytes and viable embryos, which can be cryopreserved and used for frozen embryo transfer with better outcomes in patients with extreme BMIs and advanced age.

TREATMENT OUTCOMES:

I. Down Regulation



II. Number of Oocytes Retrieved, MII Oocytes & Transferred Embryos



III. Pregnancy Rate

